バセドウ病の異常甲状腺刺激物質に関する臨床的検討:第一編 : ブタ甲状腺培養細胞及びPEG抽出IgGを用いた高感度thyroid-stimulating antibody (TSAb) 測定法の基礎的並びに臨床的検討
スポンサーリンク
概要
- 論文の詳細を見る
The activities of thyroid-stimulating antibody (TSAb) in serum from patients with Graves' disease were measured by a sensitive assay, using cultured porcine thyroid cells and the precipitation from serum with polyethylene glycol (PEG), and the activities were compared with those of thyrotropin binding inhibitor immunoglobulin (TBII), measured by the commercial assay kit.<BR>Porcine thyroid cells after digestion were cultured for 15-18 hours with TSH of 1-10,000μU/ml or the precipitations of sera from normal subjects and patients with Graves' disease or Hashimoto's thyroiditis, and then the cAMP levels in the culture medium were determined by the commercial RIA assay kit (Yamasa). The precipitation was obtained by adding 0.5ml of 30% PEG solution to 0.5ml serum, and was resuspended with 0.6ml of Hanks' medium without NaCl, containing 1.5% bovine serum albumin, 20mM Hepes and 0.5mM 3-isobutyl-1-methylxanthine. The precipitation contained about 85% of immunoglobulin and 63% of albumin of the original amount of the serum, as well as substantial TSH, when the original serum contained TSH more than 40μU/ml.<BR>When the PEG precipitations from 10 normal subjects were incubated with the thyroid cells of 4 × 10<SUP>5</SUP> cells, the cAMP releases into the medium ranged from 83 to 124%, when the mean value was calculated as 100%. Therefore, the cAMP release of more than 130% of the amount released into the culture medium when incubated with normal IgG was judged as positive TSAb activity. The minimum detectable quantities were regarded as about 5μU/ml TSH equivalent.<BR>TSAb and TBII activities were detected in 48 (92%) and 50 (96%) of 52 patients with untreated hyperthyroid Graves' disease, respectively, and either TSAb or TBII activities were detected in 16 (80%) of 20 patients with Graves' disease maintained in a clinically euthyroid state by treatment with antithyroid drugs. TBII was positive in 10 (50%) of these patients. Some patients showed distinct discrepancies in these two activities, although there was a significant positive correlation between TSAb and TBII activities (r=0.53, p<0.01) in patients with untreated Graves' disease. In these patients, TSAb activities showed a significant positive correlation with values for <SUP>99m</SUP>Tc thyroid uptake, determined 30 min after the injection. However, they did not show any significant correlation with serum T<SUB>4</SUB> or T<SUB>3</SUB> concentrations. Similarly, TBII showed significant correlations with goiter size and <SUP>99m</SUP>Tc thyroid uptake.<BR>To conclude, the present assay for TSAb is sensitive and reproducible. Although these two activities are not always equally detected in these patients, the TSAb and/or TBII activities are detected in virtually all patients with untreated hyperthyroid Graves' disease, suggesting that these activities are important for the etiology of Graves' disease.
- 一般社団法人 日本内分泌学会の論文
著者
関連論文
- サイログロブリン(Tg) (広範囲 血液・尿化学検査 免疫学的検査(第7版・4)その数値をどう読むか) -- (内分泌学的検査 甲状腺・副甲状腺関係)
- 甲状腺疾患に関するアンケート調査
- 続発性上皮小体機能亢進症に対する手術治療
- 維持透析患者における虚血性心疾患のスクリーニング : 心臓超音波検査による左室局所性壁運動異常の有用性
- 慢性維持透析患者における十全大補湯の有用性の検討
- ネフローゼ症候群を伴った慢性腎不全に対する腹膜透析療法
- 甲状腺分化癌の統計と予後因子の検討
- 慢性甲状腺炎(橋本病),甲状腺機能低下症 (特集 甲状腺疾患をマスターする) -- (甲状腺機能低下症)
- 薬剤による甲状腺障害
- 甲状腺機能異常